Gallus BioPharmaceuticals Enters Agreement with Omni Bio Pharmaceutical - - BioPharm International

ADVERTISEMENT

Gallus BioPharmaceuticals Enters Agreement with Omni Bio Pharmaceutical



Gallus BioPharmaceuticals, a CMO, and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alpha-1 antitrypsin (AAT), reported the finalization of a multi-stage manufacturing services agreement.

The agreement includes cell line optimization, analytical development, and manufacturing scale-up activities for Omni Bio’s AAT Fc fusion protein with the goal of providing cGMP product to support animal toxicology studies and early clinical trials of the molecule. Under the agreement, Omni Bio has selected the commercially available Chozn GS Cell line from Sigma-Aldrich’s custom manufacturing and services business unit SAFC Commercial as the expression system. In addition, SAFC will perform the cell line development and safety testing services, in conjunction with Gallus’ overall management of the process development and manufacturing services program for Omni Bio.

Source: Gallus BioPharmaceuticals
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here